UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Cassava Sciences, Inc. (NASDAQ:SAVA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) by 23.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,084 shares of the company’s stock after acquiring an additional 14,190 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.16% of Cassava Sciences worth $177,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Two Sigma Advisers LP purchased a new position in Cassava Sciences in the fourth quarter valued at about $1,432,000. Two Sigma Investments LP grew its stake in shares of Cassava Sciences by 679.1% in the fourth quarter. Two Sigma Investments LP now owns 562,082 shares of the company’s stock valued at $1,327,000 after buying an additional 489,936 shares in the last quarter. MYDA Advisors LLC acquired a new stake in shares of Cassava Sciences in the fourth quarter valued at about $400,000. XTX Topco Ltd purchased a new stake in shares of Cassava Sciences during the 4th quarter valued at about $220,000. Finally, Aristides Capital LLC lifted its position in Cassava Sciences by 588.6% during the 4th quarter. Aristides Capital LLC now owns 62,542 shares of the company’s stock worth $148,000 after acquiring an additional 75,342 shares in the last quarter. 38.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of Cassava Sciences in a research report on Tuesday, March 25th.

Cassava Sciences Trading Up 1.4%

SAVA opened at $2.12 on Friday. Cassava Sciences, Inc. has a twelve month low of $1.15 and a twelve month high of $42.20. The firm has a market cap of $102.41 million, a price-to-earnings ratio of -1.54 and a beta of -1.99. The company has a fifty day simple moving average of $1.77 and a 200 day simple moving average of $2.29.

Cassava Sciences (NASDAQ:SAVA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.48) earnings per share for the quarter. On average, analysts forecast that Cassava Sciences, Inc. will post -3.97 earnings per share for the current fiscal year.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.